Adamantyl-THPINACA
Legal status
Legal status
Identifiers
  • N-(2-Adamantyl)-1-(tetrahydropyran-4-ylmethyl)indazole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H31N3O2
Molar mass393.531 g·mol−1
3D model (JSmol)
  • C12C(C3CC(CC(C1)C3)C2)NC(=O)C2=NN(C3=CC=CC=C23)CC2CCOCC2
  • InChI=1/C24H31N3O2/c28-24(25-22-18-10-16-9-17(12-18)13-19(22)11-16)23-20-3-1-2-4-21(20)27(26-23)14-15-5-7-29-8-6-15/h1-4,15-19,22H,5-14H2,(H,25,28)/f/h25H
  • Key:XFZLBNDGZVRJNJ-UHFFFAOYSA-N

Adamantyl-THPINACA (ATHPINACA, AD-THPINACA)[1] is an indazole-based synthetic cannabinoid,[2] which was first reported to Europol in Slovenia in January 2015.[3] It is known as both the 1-adamantyl and 2-adamantyl isomers (SGT-40 and SGT-194 respectively), which can be distinguished by GC-EI-MS.[4] It is banned in Sweden[5] and Russia.[6] Both the 1-adamantyl and 2-adamantyl isomers are specifically listed as illegal drugs in Japan.[7] Given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, it is suspected that metabolic hydrolysis of the amide group of Adamantyl-THPINACA may also release amantadine.

See also

References

  1. ↑ "ATHPINACA isomer 1 (CAS 1400742-48-4)". Caymen Chemical. Retrieved 29 April 2017.
  2. ↑ "Muuntohuumeiden esiintyvyys 2015" (PDF). Finnish Medicines Agency. 7 May 2015. Retrieved 10 March 2021.
  3. ↑ Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA
  4. ↑ Asada A, Doi T, Tagami T, Takeda A, Sawabe Y (March 2017). "Isomeric discrimination of synthetic cannabinoids by GC-EI-MS: 1-adamantyl and 2-adamantyl isomers of N-adamantyl carboxamides". Drug Testing and Analysis. 9 (3): 378–388. doi:10.1002/dta.2124. PMID 27770510.
  5. ↑ "Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. Retrieved 24 July 2015.
  6. ↑ List of substances prohibited in the Russian Federation
  7. ↑ 指定薬物一覧
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.